Asthma,COPD
Conditions
Interventions
Group B:Group A, on the first day, traditional manual pressure quantitative inhaler is used, and on the second day, inhalation triggered aerosol automatic inhaler is used. The bronchodilator is salbut
Group A:Group B, on the first day, an inhalation triggered aerosol automatic inhaler is used, and on the second day, a traditional manual pressure quantitative inhaler is used. The bronchodilator is s
Sponsors
The First Affiliated Hospital of Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Agree to participate in this experiment and have the subject or their legal representative sign an informed consent form; (2) Age between 18-80 years old; (3) FEV1 accounts for 30-70% of the expected value; (4) A bronchial dilation test is required, and the estimated dilation test result is positive.
Exclusion criteria
Exclusion criteria: (1) Those who are allergic to the inhaled drug of the study; (2) ß2-class receptor agonists are prohibited for patients with severe cardiac insufficiency, and cholinergic receptor antagonists are prohibited for patients with glaucoma and prostatic hypertrophy; (3) There are other contraindications that are not suitable for pulmonary function tests for forced ventilation; 1) Myocardial infarction, stroke, shock in the past 3 months; 2) Severe cardiac insufficiency, severe arrhythmia, unstable angina, and massive hemoptysis in the past 4 weeks; 3) seizures need to be controlled by medication; Severe illness or delirium, mental disorders, etc.; 4) Uncontrolled hypertension (systolic blood pressure > 200 mmHg, diastolic blood pressure > 100 mmHg); 5) Heart rate>120 beats/min, aortic aneurysm, severe hyperthyroidism; 6) perforation of the tympanic membrane; 7) pregnant women; 8) Pneumothorax, giant bullae and not ready for surgery; 9) Patients with severe glaucoma, ocular surgery within 1~3 months, etc., who are not suitable for intraocular pressure increase; 10) Recent respiratory tract infection (< 4 weeks), respiratory infectious diseases (tuberculosis, influenza, coronavirus infectious pneumonia, etc.), acute phase of infectious diseases (such as various types of pneumonia), etc.; (4) Those who are considered by the investigator to have any other conditions that are not suitable for induction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum volume and rate of FEV1 change; | — |
Secondary
| Measure | Time frame |
|---|---|
| Volume and maximum rate of FVC change;Positive rate of bronchial dilation test; | — |
Countries
China
Contacts
Public ContactZeng Huiqing
The First Affiliated Hospital of Guangzhou Medical University
Outcome results
None listed